Monitoring steroid diabetes in kidney disease patients
A Study on the Influencing Factors of Glucocorticoid Induced Elevated Blood Glucose in Nephrotic Patients
Zhejiang Provincial People's Hospital · NCT06161701
This study is tracking patients with nephrotic syndrome who are starting steroid treatment to see if they develop high blood sugar and to help manage it early on.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Zhejiang Provincial People's Hospital (other) |
| Drugs / interventions | prednisone |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06161701 on ClinicalTrials.gov |
What this trial studies
This observational study follows patients with nephrotic syndrome who are starting glucocorticoid treatment to monitor for the development of steroid diabetes. It involves regular assessments of blood sugar levels and medication usage over a one-year period. The goal is to identify and intervene in cases of elevated blood sugar promptly to prevent irreversible damage. Patients with pre-existing diabetes or certain other conditions are excluded from participation.
Who should consider this trial
Good fit: Ideal candidates are patients with nephrotic syndrome who are beginning glucocorticoid therapy and do not have a history of diabetes.
Not a fit: Patients with pre-existing diabetes or those unable to comply with blood glucose monitoring will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to timely identification and management of steroid diabetes in kidney disease patients, improving their overall health outcomes.
How similar studies have performed: While the approach of monitoring steroid diabetes in nephrotic syndrome patients is not widely tested, similar observational studies have shown the importance of early detection in managing diabetes related to steroid use.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who need to use glucocorticoids due to the following diseases: nephrotic syndrome, Immunoglobulin A nephropathy, membranous nephropathy, Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), systemic lupus erythematosus； 2. Initial daily dose of glucocorticoids greater than or equal to 10mg of prednisolone； Exclusion Criteria: 1. Patients with diabetes； 2. Those who are unable to communicate through language； 3. Uremic patients； 4. Unable to perform blood glucose monitoring and follow-up as required； 5. Those who have used glucocorticoids within the past 3 months and have accumulated a dose of 10mg or more of prednisone； 6. Participated in other clinical studies。
Where this trial is running
Hangzhou, Zhejiang
- Zhejiang provincial people's hospital — Hangzhou, Zhejiang, China (RECRUITING)
Study contacts
- Study coordinator: Xiaolan Ye, master
- Email: yexl1120@126.com
- Phone: +86-0571-85893117
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Nephrotic Syndrome, steroid diabetes